Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics' Colorectal Cancer Test Approved in Argentina

NEW YORK (GenomeWeb News) – Epigenomics and VSA Alta Complejidad today announced that VSA has been approved to market Epigenomics' Epi proColon kit in Argentina.

The companies have worked together since last year to secure regulatory approval for Epigenomics' blood-based colorectal cancer test from ANMAT, which regulates diagnostic tests in Argentina. They also said that VSA has forged relationships with leading diagnostic reference laboratories in Argentina to make Epi proColon available there.

"This makes Argentina the first country outside Europe to have granted approval for our test," Noel Doheny, CEO of Epigenomics' US subsidiary, said in a statement. "Given VSA's significant diagnostic testing skill set, combined with a keen focus on the colorectal cancer space, we believe VSA is an ideal partner for Epigenomics."

A US Food and Drug Administration panel is scheduled review the firm's premarket approval submission to the agency for Epi proColon later this month.